Asia Pacific
Refine Search
Biotechnology
Japanese drugmaker Eisai and US biotech Biogen (announced that their humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody Leqembi (lecanemab) has been launched in China. 28 June 2024
Pharmaceutical
UCB ( has received marketing approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) has granted marketing authorization for Briviact (brivaracetam). 26 June 2024
Pharmaceutical
Danish drugmaker Novo Nordisk’s GLP-1 receptor agonist Wegovy (semaglutide) has been approved in China for long-term weight management. 26 June 2024
Biotechnology
US pharma major AstraZeneca (LSE: AZN) today revealed that its Tagrisso (osimertinib) with the addition of pemetrexed and platinum-based chemotherapy has been approved in Japan . 25 June 2024
Biotechnology
UK health technology assessor the National Institute for Health and Care Excellence (NICE) has approved Crysvita (burosumab) from Japanese drugmaker Kyowa Kirin. 21 June 2024
Pharmaceutical
Spanish plasma-derived products specialist Grifols announced it has completed the sale of a 20% equity stake in Shanghai RAAS (SRAAS) to Haier Group Corp. 20 June 2024
Biotechnology
Shanghai-based Dizal Pharmaceutical announced that the National Medical Products Administration of China has approved golidocitinib. 20 June 2024
Pharmaceutical
Midsize Japanese drugmaker Otsuka Pharmaceuticals says it has concluded an expanded licensing agreement for hereditary angioedema (HAE) drug candidate donidalorsen with Ionis Pharmaceuticals to cover the development and sales area to the Asia-Pacific region, including Japan. 20 June 2024
Pharmaceutical
The US unit of Japan’s Mitsubishi Tanabe Pharma has announced results from two studies of its already marketed Radicava (edaravone) for amyotrophic lateral sclerosis (ALS) at the European Network to Cure Amyotrophic Lateral Sclerosis (ENCALS) 2024 meeting. 18 June 2024
Pharmaceutical
Takeda, Japan’s largest drugmaker, today announced mixed top-line data from its SKYLINE and SKYWAY Phase III trials outcomes for its drug soticlestat. 17 June 2024
Biotechnology
German biotech BioNTech today announced that it has been informed by its partner, China’s MediLink Therapeutics (Suzhou), that the US Food and Drug Administration (FDA) has placed a partial clinical hold on a trial of their antibody-drug conjugate (ADC). 17 June 2024
Pharmaceutical
Japanese drugmaker Mitsubishi Tanabe Pharma (MTPC) has entered into an agreement with Paris, France-based Ethypharm for the transfer of the business of the selective antithrombin agent, argatroban monohydrate in Europe. 17 June 2024
Biotechnology
At a meeting with Brazil’s Vice President and Minister of Development, Industry and Commerce Geraldo Alckmin, in Beijing, Chinese vaccine developer Sinovac Biotech announced that it will invest $100 million in the development of cell therapy, vaccine production and monoclonal antibodies in Brazil. 17 June 2024
Biotechnology
Japanese drugmaker Takeda has signed an option agreement with China’s Ascentage Pharma to enter into an exclusive license agreement for olverembatinib. 14 June 2024
Biotechnology
China’s Innovent Biologics recently presented Phase I study results of its first-in-class anti-CLDN18.2/CD3 bispecific antibody (IBI389) for the treatment of advanced pancreatic cancer. 14 June 2024
Biosimilars
South Korea’s Samsung Bioepis today presented the post-hoc analysis of the Phase III clinical study results for Epysqli (SB12), a biosimilar to AstraZeneca’s Soliris (eculizumab), at the EHA Congress. 14 June 2024
Biotechnology
US drugmaker AbbVie and China’s FutureGen Biopharmaceutical have announced a license agreement to develop FG-M701, a next generation TL1A antibody for the treatment of inflammatory bowel disease (IBD), currently in preclinical development. 13 June 2024
Biotechnology
The Center for Drug Evaluations of the National Medical Products Administration (NMPA) in China has accepted the biologics license application (BLA) for zanidatamab for second-line treatment of HER2-positive biliary tract cancer (BTC). 11 June 2024
Biotechnology
Japanese drugmaker Kyowa Kirin yesterday revealed it is establishing a new, state-of-the-art manufacturing facility in Sanford, North Carolina, in the USA. 11 June 2024
Biosimilars
As the BIOSECURE Act progresses through the US legislative process, the US pharmaceutical industry finds itself at a crossroads. 10 June 2024
Pharmaceutical
Japanese drugmaker Eisai has announced that the amyotrophic lateral sclerosis (ALS) treatment Rozebalamin for Injection (mecobalamin) has been launched in Japan as a treatment for slowing progression of functional impairment in amyotrophic lateral sclerosis. 21 November 2024
Biotechnology
San Diego-based Kura Oncology and Japan’s Kyowa Kirin have entered into a global strategic collaboration to develop and commercialize ziftomenib. 21 November 2024
Pharmaceutical
Shanghai-based Leading Tac Pharmaceutical has announced the successful completion of a series A financing round, raising over 100 million yuan ($14 million). 21 November 2024
Pharmaceutical
Ascentage Pharma will see its investigational BCL-2 selective inhibitor, lisaftoclax, assessed under China’s Priority Review scheme. 20 November 2024
Pharmaceutical
California, USA-based biotech Cytokinetics saw its shares fall as much as 4% to $9.67 yesterday, after it announced a deal with Germany’ Bayer. 20 November 2024
Biotechnology
Californian oncology-focused biotech Avenzo Therapeutics has announced a pair of important updates. 19 November 2024
Pharmaceutical
Big pharmas are not deterred by China’s increasingly complex business environment. Instead, they are changing strategies to minimize risks while continuing to benefit from China, said speakers at ChinaTrials held last week in Shanghai. 18 November 2024
Biosimilars
Following US approval in May this year, South Korea’s Samsung Bioepis and US biotech Biogen have now won approval from the European Commission (EC) for their Opuviz 40mg/mL solution for injection in a vial, a biosimilar referencing Regeneron and Bayer’s Eylea (aflibercept). 18 November 2024
Biotechnology
Shanghai-based Junshi Biosciences has received UK regulatory approval for Loqtorzi (toripalimab) in nasopharyngeal carcinoma (NPC) and esophageal squamous cell carcinoma (ESCC). 18 November 2024
Biotechnology
Chinese biotech Keymed Biosciences has entered an exclusive licensing agreement with Platina Medicines for its bispecific antibody candidate, CM336. 18 November 2024
Pharmaceutical
In yet another sign of the mounting interest in radiopharmaceuticals, Tongrui Biopharma, a Chinese innovator in this area, has announced the completion of a $100 million series A+ financing round. 18 November 2024
Biotechnology
Shanghai-based biopharma Zai Lab has announced the pricing of its underwritten public offering at $25.50 per share, aiming to raise around $200 million. 15 November 2024
Biosimilars
South Korean biosimilars company Celltrion today announced its acquisition of iQone Healthcare Switzerland a specialty pharmaceutical company focused on distribution, sales, and marketing in Switzerland. 15 November 2024
Biotechnology
Merck & Co has entered into an exclusive global license to develop, manufacture and commercialize LM-299 from China-based clinical-stage biotech LaNova Medicines, bringing the US pharma giant into the newly attractive PD-1/VEGF bispecific antibody space. 15 November 2024
Biotechnology
Japanese drugmaker Nippon Shinyaku and USA-based Atsena Therapeutics have entered into an exclusive license agreement for the commercialization of ATSN-101 in the USA and Japan for advancing Atsena’s first- in-class, investigational gene therapy ATSN-101 for Leber congenital amaurosis caused by biallelic mutations in GUCY2D (LCA1). 13 November 2024
Biotechnology
Anglo-American biotech Apollo Therapeutics and China-based Sunshine Lake Pharma have signed an exclusive license agreement to develop APL-18881, a bi-specific fusion protein aimed at treating metabolic diseases. 13 November 2024
Biotechnology
Dutch firm Argenx and China’s Zai Lab have received an approval from the National Medical Products Administration (NMPA) for Vyvgart Hytrulo (efgartigimod alfa). 13 November 2024
Biotechnology
Although it is seeing a downturn in sales and profits, German biotech BioNTech is continuing to acquire assets with the cash pile it made through the covid pandemic, notably iis Comirnaty vaccine that was developed with Pfizer (NYSE: PFE). 13 November 2024
Biotechnology
Sino-American oncology company BeiGene has announced third-quarter 2024 financials, showing the total revenues was $1,002 million, up 28% compared to $781 million in the same period of 2023. 13 November 2024
Pharmaceutical
Li Li, Commissioner of China's National Medical Products Administration (NMPA), and Mette Aaboe Hansen, interim director general of Danish Medicines Agency, have signed a letter of intent to promote bilateral cooperation in regulation of drugs and medical devices. 11 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze